256 related articles for article (PubMed ID: 24809734)
21. Invasion is not an independent prognostic factor in high-grade glioma.
Narayana A; Perretta D; Kunnakkat S; Gruber D; Golfinos J; Parker E; Medabalmi P; Zagzag D; Pat Eagan RN; Gruber M
J Cancer Res Ther; 2011; 7(3):331-5. PubMed ID: 22044816
[TBL] [Abstract][Full Text] [Related]
22. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
[TBL] [Abstract][Full Text] [Related]
23. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
27. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
28. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):70-7. PubMed ID: 22022926
[TBL] [Abstract][Full Text] [Related]
29. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
[TBL] [Abstract][Full Text] [Related]
30. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.
Coffelt SB; Tal AO; Scholz A; De Palma M; Patel S; Urbich C; Biswas SK; Murdoch C; Plate KH; Reiss Y; Lewis CE
Cancer Res; 2010 Jul; 70(13):5270-80. PubMed ID: 20530679
[TBL] [Abstract][Full Text] [Related]
31. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases.
Miyatake S; Furuse M; Kawabata S; Maruyama T; Kumabe T; Kuroiwa T; Ono K
Neuro Oncol; 2013 Jun; 15(6):650-5. PubMed ID: 23460324
[TBL] [Abstract][Full Text] [Related]
33. Invasion as limitation to anti-angiogenic glioma therapy.
Lamszus K; Kunkel P; Westphal M
Acta Neurochir Suppl; 2003; 88():169-77. PubMed ID: 14531575
[TBL] [Abstract][Full Text] [Related]
34. δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion.
Shimizu T; Ishida J; Kurozumi K; Ichikawa T; Otani Y; Oka T; Tomita Y; Hattori Y; Uneda A; Matsumoto Y; Date I
Mol Cancer Ther; 2019 Apr; 18(4):812-822. PubMed ID: 30872378
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab at recurrence in high-grade glioma.
Salmaggi A; Gaviani P; Botturi A; Lamperti E; Simonetti G; Ferrari D; Silvani A
Neurol Sci; 2011 Nov; 32 Suppl 2():S251-3. PubMed ID: 21987287
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
[TBL] [Abstract][Full Text] [Related]
37. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
[TBL] [Abstract][Full Text] [Related]
39. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
40. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
Piao Y; Liang J; Holmes L; Henry V; Sulman E; de Groot JF
Clin Cancer Res; 2013 Aug; 19(16):4392-403. PubMed ID: 23804423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
